AR and prostate carcinoma: One potentially important mechanism is the maintenance of androgen receptor (AR) signalling in hormone-refractory prostate cancer by crosstalk between AR and nonsteroidal molecules, including cytokines and growth factors (Culig et al, 1994; Craft et al, 1999; Culig, 2004; Wang et al, 2008).